

Walid L Shaib

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2101855/publications.pdf>

Version: 2024-02-01

63
papers

1,733
citations

279778

23
h-index

302107

39
g-index

63
all docs

63
docs citations

63
times ranked

3020
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. <i>British Journal of Cancer</i> , 2019, 121, 809-818.	6.4	232
2	Appendiceal Mucinous Neoplasms: Diagnosis and Management. <i>Oncologist</i> , 2017, 22, 1107-1116.	3.7	131
3	The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. <i>Cancer</i> , 2019, 125, 127-134.	4.1	120
4	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. <i>BMC Cancer</i> , 2019, 19, 857.	2.6	88
5	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. <i>Cancer</i> , 2020, 126, 575-582.	4.1	65
6	Inhibition of NF- κ B translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. <i>Cancer Letters</i> , 2016, 373, 227-233.	7.2	63
7	A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 296-303.	0.8	61
8	Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases. <i>Modern Pathology</i> , 2016, 29, 1243-1253.	5.5	53
9	Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. <i>Oncologist</i> , 2016, 21, 178-187.	3.7	47
10	Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. <i>International Journal of Cancer</i> , 2019, 145, 1529-1537.	5.1	46
11	Incidence and Survival of Appendiceal Mucinous Neoplasms. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 569-573.	1.3	45
12	Markers of resistance to anti-EGFR therapy in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 308-18.	1.4	45
13	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. <i>Oncologist</i> , 2020, 25, e528-e535.	3.7	44
14	High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. <i>Oncologist</i> , 2019, 24, 911-920.	3.7	39
15	Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. <i>European Journal of Cancer</i> , 2016, 52, 109-119.	2.8	38
16	Non-ampullary duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas. <i>Modern Pathology</i> , 2017, 30, 255-266.	5.5	36
17	Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 74-81.	1.3	36
18	Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer. <i>Molecular Carcinogenesis</i> , 2017, 56, 288-299.	2.7	35

#	ARTICLE	IF	CITATIONS
19	Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. <i>JCI Insight</i> , 2020, 5, .	5.0	31
20	Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. <i>Cancer Research and Treatment</i> , 2016, 48, 596-604.	3.0	30
21	Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. <i>Oncotarget</i> , 2020, 11, 1749-1757.	1.8	29
22	Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults. <i>Cancer Epidemiology</i> , 2019, 63, 101618.	1.9	26
23	Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers. <i>Oncologist</i> , 2015, 20, 907-914.	3.7	25
24	Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 85-94.	1.4	24
25	Clinical Outcomes of Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2019, 18, 257-268.	2.3	24
26	Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. <i>Cancer</i> , 2017, 123, 4924-4933.	4.1	20
27	Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. <i>Cancer</i> , 2018, 124, 1992-2000.	4.1	17
28	A multi-center, single-arm, phase 1b study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN G14-186. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3337-3348.	4.2	16
29	Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Oncologist</i> , 2018, 23, 704-711.	3.7	15
30	<p>Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 119-129.	3.7	15
31	Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. <i>Cancer</i> , 2019, 125, 57-67.	4.1	15
32	Discussing molecular testing in oncology care: Comparing patient and physician information preferences. <i>Cancer</i> , 2017, 123, 1610-1616.	4.1	14
33	Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies. <i>Targeted Oncology</i> , 2021, 16, 461-469.	3.6	14
34	In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. <i>Journal of Geriatric Oncology</i> , 2020, 11, 660-667.	1.0	13
35	Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 556-560.	1.7	12
36	Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1006-1014.	2.0	12

#	ARTICLE	IF	CITATIONS
37	Young Adults With Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 341-354.	1.1	12
38	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , 2019, 37, 1198-1206.	2.6	11
39	Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers. <i>Oncologist</i> , 2020, 25, 414-421.	3.7	11
40	The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma. <i>Journal of Clinical Medicine</i> , 2016, 5, 100.	2.4	10
41	Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival. <i>Frontiers in Oncology</i> , 2021, 11, 728076.	2.8	10
42	Using Metaphors to Explain Molecular Testing to Cancer Patients. <i>Oncologist</i> , 2017, 22, 445-449.	3.7	9
43	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2497-2505.	7.0	9
44	Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status. <i>Frontiers in Oncology</i> , 2021, 11, 592351.	2.8	9
45	TTF-1 Expression in Rectal Adenocarcinoma: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2017, 9, 747-751.	0.7	8
46	The Impact of Genetic Counseling Educational Tools on Patients's Knowledge of Molecular Testing Terminology. <i>Journal of Cancer Education</i> , 2020, 35, 864-870.	1.3	8
47	Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer. <i>Journal of Surgical Oncology</i> , 2020, 121, 294-302.	1.7	8
48	Induction Therapy in Localized Pancreatic Cancer. <i>Pancreas</i> , 2019, 48, 913-919.	1.1	7
49	Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix?. <i>Surgical Oncology</i> , 2021, 36, 120-129.	1.6	7
50	High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 755113.	2.8	7
51	Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. <i>Cancer</i> , 2020, 126, 4136-4147.	4.1	6
52	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1228-1234.	6.4	6
53	Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. <i>Oncology</i> , 2022, 100, 131-139.	1.9	5
54	Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes. <i>Journal of Surgical Oncology</i> , 2021, 123, 596-605.	1.7	3

#	ARTICLE	IF	CITATIONS
55	Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. <i>Clinical Colorectal Cancer</i> , 2021, 20, 153-160.	2.3	3
56	Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 822-829.	1.1	2
57	Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors. <i>Pancreas</i> , 2021, 50, 1382-1391.	1.1	2
58	Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer. <i>Oncologist</i> , 2022, 27, 740-750.	3.7	2
59	Impact of high-risk features for stage II adenocarcinoma of the appendix. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100329.	1.7	1
60	Survival Outcomes of Acinar Cell Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 529-536.	1.1	1
61	Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 477-486.	0.5	0
62	Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States. <i>World Journal of Oncology</i> , 2015, 6, 349-354.	1.5	0
63	In Reply. <i>Oncologist</i> , 2020, 25, e2021-e2021.	3.7	0